<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170959</url>
  </required_header>
  <id_info>
    <org_study_id>OPM-RADFORMIN-1801</org_study_id>
    <nct_id>NCT04170959</nct_id>
  </id_info>
  <brief_title>The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC</brief_title>
  <acronym>RADFORMIN</acronym>
  <official_title>Randomized Phase II Trial of Definitive Radiotherapy With or Without metFORMin in Patients With Inoperable Stage III Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ethisch.comite@uza.be</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stand Up To Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study the effect of metformin when added to definitive locoregional radiotherapy on&#xD;
      locoregional control and relapse rate in stage III non-small cell lung cancer patients&#xD;
      receiving sequential chemoradiotherapy. Try to identify subsets of patients who derive&#xD;
      maximum benefit of adding metformin to radiotherapy using innovative biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The administration of oral metformin during radiotherapy is thought to decrease the hypoxic&#xD;
      fraction of tumour cells, improving radiosensitivity and promoting apoptosis, resulting in&#xD;
      better outcome. This hypothesis will be evaluated in a trial with randomized design. All&#xD;
      patients willing to participate will receive definitive radiotherapy, either in combination&#xD;
      with metformin (arm C) or without metformin (arm B). Patients who refuse to participate in&#xD;
      the randomized part can be included in the observational arm of the study (arm A). In&#xD;
      addition, the validated biomarker of tumour hypoxia (18F-HX4 PET/CT scintigraphy&#xD;
      (18F-flortanidazole positron emission computed tomography) and biomarkers of resistance,&#xD;
      apoptosis and glucose metabolism will be evaluated for their potential predictive value.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Loss of external funding&#xD;
  </why_stopped>
  <start_date type="Actual">July 30, 2018</start_date>
  <completion_date type="Actual">January 8, 2021</completion_date>
  <primary_completion_date type="Actual">January 8, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective multicentre trial, consisting of an observational lead-in phase and a randomized phase II using a 1:1 ratio. All patients willing to participate will receive definitive radiotherapy either in combination with metformin (arm C) or without metformin (arm B).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Loco regional progression-free survival rate</measure>
    <time_frame>1 year after start of treatment</time_frame>
    <description>(LPFS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>time until death; assessed up to 60 months after treatment start</time_frame>
    <description>(OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>earliest date of disease progression (local or distant), assessed up to 24 months after treatment start</time_frame>
    <description>(PFS)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>A: Observational arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Radiotherapy as per standard of care without metformin, no additional biomarkers/imaging will be performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Control arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Radiotherapy as per standard of care without metformin, with additional biomarkers/imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Interventional arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy as per standard of care with metformin, with additional biomarkers/imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500 mg given 14 days before start until the end of radiation therapy. Once daily during the first 7 days, afterwards twice daily until the end of treatment.</description>
    <arm_group_label>C: Interventional arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No metformin</intervention_name>
    <description>Standard of care without metformin.</description>
    <arm_group_label>B: Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed and dated informed consent form.&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Ability to take oral medication and willing to adhere to the RADFORMIN-regimen.&#xD;
&#xD;
          -  Male or female, â‰¥ 18 years of age.&#xD;
&#xD;
          -  Histological or cytological proven stage III NSCLC after adequate staging with at&#xD;
             least 18F-2-fluoro-2-deoxy-D-glucose (FDG) PET/CT, contrast enhanced CT-thorax and&#xD;
             contrast-enhanced CT/MRI brain. (According to 8th edition of TNM classification (=&#xD;
             tumor, node, metastasis))&#xD;
&#xD;
          -  Absence of diabetes, (diabetes is defined as fasting plasma glucose &gt;126 mg/dL or&#xD;
             random plasma glucose &gt;200 mg/dL).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance score (= World Health&#xD;
             Organization (WHO) score) of 0-1.&#xD;
&#xD;
          -  Adequate hematologic, hepatic and renal function as clinically acceptable in the&#xD;
             opinion of the Primary Investigator.&#xD;
&#xD;
          -  Adequate pulmonary function in order to be administered definitive radiotherapy. With&#xD;
             Forced Expiratory Volume (FEV) &gt; 1.2 litres per second or more than 50% of predicted,&#xD;
             and diffusion capacity of lung for carbon monoxide (DLCO) &gt; 40% predicted. (Values&#xD;
             without administration of medical bronchodilation. In case of Tiffeneau &lt; 70%&#xD;
             bronchodilation will be administered)&#xD;
&#xD;
          -  Having received at least 2 cycles of platinum-based chemotherapy. This according to&#xD;
             institutional standards and without progression (on a restaging CT-scan within 3 weeks&#xD;
             after day 1 of the last given cycle, according to RECIST criteria).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use of metformin, insulin or other oral antidiabetic drugs&#xD;
             (thiazolidinediones, sulfonylureas, mitiglinides, alpha-glucosidase inhibitors,&#xD;
             incretin mimetics, dipeptidyl peptidase-4 inhibitors, amylin analogues,&#xD;
             sodium-glucose-cotransporter-2 (SGLT-2)-inhibitors) for any reason.&#xD;
&#xD;
          -  Evidence for metastatic disease.&#xD;
&#xD;
          -  Conditions associated with increased risk of metformin-associated lactic acidosis: New&#xD;
             York Heart Association class III or IV congestive heart failure, history of acidosis&#xD;
             of any type, known kidney injury or disease, alcoholic liver disease or habitual&#xD;
             intake of 3 or more alcoholic beverages per day.&#xD;
&#xD;
          -  Known pregnancy or lactating female patients.&#xD;
&#xD;
          -  Known allergic reactions to components of metformin.&#xD;
&#xD;
          -  Prior invasive malignancy within the past year (in remission, without evidence for&#xD;
             current active disease and without maintenance therapy). Except non-melanomatous skin&#xD;
             cancer, non-invasive carcinoma in-situ of the breast, oral cavity or cervix.&#xD;
&#xD;
          -  Known acquired immune deficiency syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan van Meerbeeck, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>P.I.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>ethisch.comite@uza.be</investigator_full_name>
    <investigator_title>Head of Department Thoracic Oncology + Principal Investigator (Prof. Dr. Jan van Meerbeeck)</investigator_title>
  </responsible_party>
  <keyword>Tumor Hypoxia</keyword>
  <keyword>Metformin</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

